within Pharmacolibrary.Drugs.ATC.C;

model C02LC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 10 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.15 / 1000000,
    adminCount     = 1,
    Vd             = 0.0021000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Fixed combination of clonidine (an alpha-2 adrenergic agonist antihypertensive) and a diuretic, used in treatment of hypertension, particularly where monotherapy is inadequate. The ATC code C02LC01 refers specifically to fixed combinations. Such combinations have historical but limited modern use and may not be widely available or recommended in current guidelines.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies exist for the fixed combination formulation of clonidine and diuretics under ATC code C02LC01. Therefore, PK parameters are estimated based on typical oral clonidine and thiazide diuretic profiles in adults.</p><h4>References</h4><ol><li><p>MacCarthy, EP, &amp; Bloomfield, SS (1983). Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. <i>Pharmacotherapy</i> 3(4) 193–219. DOI:<a href=&quot;https://doi.org/10.1002/j.1875-9114.1983.tb03252.x&quot;>10.1002/j.1875-9114.1983.tb03252.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6310529/&quot;>https://pubmed.ncbi.nlm.nih.gov/6310529</a></p></li><li><p>Sica, DA, &amp; Grubbs, R (2005). Transdermal clonidine: therapeutic considerations. <i>Journal of clinical hypertension (Greenwich, Conn.)</i> 7(9) 558–562. DOI:<a href=&quot;https://doi.org/10.1111/j.1524-6175.2005.04133.x&quot;>10.1111/j.1524-6175.2005.04133.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16227779/&quot;>https://pubmed.ncbi.nlm.nih.gov/16227779</a></p></li><li><p>Laurent, S, &amp; Safar, M (1992). Rilmenidine: a novel approach to first-line treatment of hypertension. <i>American journal of hypertension</i> 5(4 Pt 2) 99S–105S. DOI:<a href=&quot;https://doi.org/10.1093/ajh/5.4.99s&quot;>10.1093/ajh/5.4.99s</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1350733/&quot;>https://pubmed.ncbi.nlm.nih.gov/1350733</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02LC01;
